Reckitt Benckiser Group plc (OTCMKTS:RBGLY - Get Free Report) saw a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 4,300 shares, a decrease of 97.2% from the November 30th total of 154,900 shares. Based on an average daily volume of 721,100 shares, the short-interest ratio is currently 0.0 days.
RBGLY has been the topic of several recent research reports. Barclays upgraded Reckitt Benckiser Group to a "strong-buy" rating in a research note on Friday, October 4th. Sanford C. Bernstein cut shares of Reckitt Benckiser Group from a "strong-buy" rating to a "hold" rating in a research note on Monday, November 4th. Citigroup upgraded shares of Reckitt Benckiser Group to a "strong-buy" rating in a research report on Tuesday, October 1st. JPMorgan Chase & Co. lowered shares of Reckitt Benckiser Group from an "overweight" rating to a "neutral" rating in a report on Thursday, August 29th. Finally, UBS Group upgraded Reckitt Benckiser Group to a "strong-buy" rating in a research report on Wednesday, September 18th. Three research analysts have rated the stock with a hold rating, one has assigned a buy rating and four have issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy".
Read Our Latest Report on RBGLY
Shares of Reckitt Benckiser Group stock traded up $0.01 on Thursday, hitting $12.05. 242,691 shares of the company traded hands, compared to its average volume of 846,842. Reckitt Benckiser Group has a 52 week low of $10.24 and a 52 week high of $15.03. The stock's 50 day moving average price is $12.32 and its 200-day moving average price is $11.77. The company has a debt-to-equity ratio of 0.97, a quick ratio of 0.47 and a current ratio of 0.69.
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Reckitt Benckiser Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reckitt Benckiser Group wasn't on the list.
While Reckitt Benckiser Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.